Abstractive Health vs Regard (2026)
Both read the whole chart and they make claims of very different size. Abstractive summarises, with every sentence traceable to its source note and an unusually honest evidence position, having published its own peer reviewed evaluation reporting that its summaries were marginally inferior to physicians. Regard recommends diagnoses and writes the note around them, gated by a clinician accepting or declining each one, with certified interoperability and quantified results at named health systems. A summary you can check line by line and a diagnostic suggestion are not the same object, and the governance bar should scale accordingly. Regard's certification examines record system criteria rather than diagnostic performance, and it publishes no accuracy figure, which is a gap that matters far more for a product that names conditions than for one that condenses text.
- It summarises the record and links every sentence to the note it came from, which is a bounded claim with traceable provenance.
- It published its own evaluation in a peer reviewed journal with a result unfavourable to the product, which is the strongest governance signal a vendor here can send.
- The compliance position is complete: a typed attestation, a public trust centre, a published business associate agreement and a published price ladder.
- It recommends diagnoses rather than summarising, on the premise that clinicians see a small fraction of the chart, and writes the note around the recommendation.
- The oversight gate is structural, with the clinician accepting or declining each recommendation and the vendor reporting how often they do.
- Interoperability is certified rather than claimed, and named health system deployments come with quantified site level results.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Abstractive Health and Regard are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Abstractive Health | Regard |
|---|---|---|
| Primary category | Clinical Summarization & Chart Review | Clinical Summarization & Chart Review |
| Founded | 2022 | 2017 |
| Headquarters | New York, NY, US | Los Angeles and New York City, US |
| Website | abstractivehealth.com | regard.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Abstractive Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Regard, Abstractive Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Regard its top capability grade on AI Centrality and EHR and Interoperability Depth. Set against Abstractive Health, Regard does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, FDA and Regulatory Status and EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Abstractive Health or Regard?
The AI Health Index grades Abstractive Health higher than Regard on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Regard does not grade higher on any scored axis.
Where do Abstractive Health and Regard differ most?
The widest separation the AI Health Index records between Abstractive Health and Regard is on Model and Technology Transparency, where Abstractive Health grades A and Regard grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Abstractive Health and Regard grade the same?
The AI Health Index grades Abstractive Health and Regard the same on several axes, including AI Centrality, FDA and Regulatory Status and EHR and Interoperability Depth. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Abstractive Health and Regard not disclosed?
At the last review, at least one of Abstractive Health and Regard published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Summarization & Chart Review page.
These are different risk objects and should not be evaluated on the same criteria: a traceable summary is checkable sentence by sentence, while a diagnostic recommendation is a clinical assertion about a patient and the certification Regard holds examines record system criteria rather than diagnostic performance. Regard publishes no accuracy figure, model card or validation publication.
Both surface documentation that improves reimbursement as well as clinical completeness, and neither separates those effects. Neither publishes an omission rate, which remains the decisive unmeasured failure in chart review.